Document is current

Article History

Received: 10 July 2023

Accepted: 14 October 2024

First Online: 15 November 2024

Declarations

:

: Massachusetts Institute of Technology (MIT) has filed several patent applications for the QTY code for GPCRs, and OH₂Laboratories has obtained a license from MIT to develop water-soluble GPCR variants. However, this article does not focus on GPCRs. One of the authors, S.Z., is an inventor of the QTY code and holds a minor equity position in OH₂Laboratories. S.Z. has also founded a startup called 511 Therapeutics, which aims to develop therapeutic monoclonal antibodies targeting solute carrier transporters for the treatment of pancreatic cancer. S.Z. holds a majority equity position in 511 Therapeutics. PT Metiska Farma partially sponsored the study but had no influence or interference in the study design, data collection, analysis, interpretation of data, manuscript writing, or decision to publish the results. All other authors declare no competing interests.

: It is a purely digital structural biology study utilizing publicly accessible in silico programs. We state that: <b>i)</b> all methods were conducted in compliance with applicable guidelines and regulations; <b>ii)</b> all experimental protocols received approval from an institutional and licensing committee; and <b>iii)</b> no human biological samples or human subjects were involved in this study.